home > pmps > autumn 2019 > hurdles in cold chain
Pharmaceutical Manufacturing and Packing Sourcer

Hurdles in Cold Chain

One of the least known but most important aspects of the airfreight cold chain is airport ground handling. This provides the vital interface between airlines that carry temperaturecritical products and local ground transportation. Increasingly, ground handling is well resourced and carefully regulated, but thatís not the case everywhere in the world, and forwardthinking handlers and airports are trying to set examples that others will follow, recognising that the airfreight cold chain is only as strong as its weakest link.

It has been many years since the air cargo industry first started carrying temperature-critical pharmaceutical and life sciences shipments and, like so many other areas of business, it has been a steep learning curve that has driven innovation, the adoption of new technology, demand for higher standards, and greatly increased scrutiny.

The great advantage of airfreight is, of course, speed. With the ready availability of non-stop flights on every major world trade lane today, itís commonplace for an airfreight shipment to take no more than a day to cross the world Ė which is an appealing proposition for maintaining condition, achieving tight deadlines, and reducing capital tied up in inventory in transit.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the author

Paul Cheng is General Manager of Service Delivery at Hong Kong Air Cargo Terminals Limited (Hactl), managing operations at the largest single general air cargo handling facility in the world. An increasing proportion of Hactlís traffic is temperaturecritical pharmaceuticals, as well as large volumes of perishables that require similar special handling facilities and processes. Hactl is widely recognised as a leader in its industry and is regularly involved in the formulation of new standards, working in conjunction with industry and regulatory bodies.

Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals initiates partnership with American Biotech Zhittya for Parkinsonís disease treatment

3P and Zhittya began their relationship at the beginning of 2019 with 3P being selected as the CDMO to transfer the process for scaling up and performing cGMP manufacturing for clinical studies. After successfully achieving transfer of the process, 3P anticipates manufacturing of the first cGMP batch by the second quarter of 2020.
More info >>

White Papers
Industry Events

SMi Presents the 4th Annual: Highly Potent Active Pharmaceutical Ingredients (HPAPI)

11-13 May 2020, Copthorne Tara Hotel, London, UK

SMi is delighted to announce its 4th Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 11th Ė 12th May 2020. HPAPI 2020 conference focuses on the growing landscape driven by the demand for highly potent drugs in oncology, diabetes and autoimmune disease treatment. This event will address the biggest challenges the industry is facing with regards to determining toxicology limits, assessing hazards, implementing risk procures, translating risk assessment into facility engineering, preventing and dealing with cross-contamination and adhering to GMP regulatory guidelines.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement